McEnany concluded, "Catalyst, along with leading addiction clinicians across the U.S., continues to seek governmental grants from the National Institutes of Health ("NIH"), the National Institute on Drug Abuse, and other agencies that operate under the NIH umbrella, for future vigabatrin addiction trials and to provide a portion of the required funding for our future clinical and non-clinical trials."
Publication of Phase II Mexican Cocaine Trial Results
A paper describing the positive results obtained in an investigator-initiated Phase II trial conducted in Mexico in 2007 was published on August 3, 2009 in the online edition of The American Journal of Psychiatry, a world leading peer-reviewed medical journal. The paper, entitled "Randomized, Double-Blind, Placebo-Controlled Trial of Vigabatrin for the Treatment of Cocaine Dependence in Mexican Parolees," was authored by Jonathan D. Brodie, M.D., Ph.D., Brady G. Case, M.D., Emilia Figueroa, M.D., Stephen L. Dewey, Ph.D., James A. Robinson, M.Ed., Joseph A. Wanderling, M.A. and Eugene M. Laska, Ph.D. The paper suggests that vigabatrin may be effective in the treatment of cocaine addiction. An abstract of the paper can be accessed by clicking here.
"We are extremely pleased that the results of this important trial have been published by a medical journal of this caliber," commented Mr. McEnany. "Catalyst is pleased to have provided financial support for this trial."
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of
|SOURCE Catalyst Pharmaceutical Partners, Inc.|
Copyright©2009 PR Newswire.
All rights reserved